Individualised Medicine in the Diagnosis and Prognosis of Patients Younger than 65 Years with Normal Karyotype Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of the Impact of Fms-Related Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD)

Matthias Port*, Miriam Böttcher*, Felicitas Thol, Nicole Trachte, Jürgen Wasem, Arnold Ganser, Laura Pouryamout* and Anja Neumann*2Individualised and personalised medicine has gained an important role in the current research into oncological and haematological diseases. The definitionof ‘individualised and personalised medicine’ is still controversial. The term as used in this article is based on biological findings leading to stratification of subgroups (for a detailed discussion on the definition of personalised medicine see Chapter 1, this volume).